Company News: ISA Pharmaceuticals Further Strengthens IP Position on Lead Compound ISA101

Three additional European patents and market exclusivity granted for the use of key active ingredients of ISA101

ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced it has strengthened the IP position of its lead compound ISA101. The European Patent Office has granted three patents (EP2267132, EP2112157, EP2468763) which relate to the use of HPV antigen-based peptides. ISA101, a novel immunotherapeutic consisting of synthetic long peptides (SLP®s), targets severe diseases triggered by human papillomavirus (HPV) infection.

The patents cover the application of a variety of long peptides derived from the E6 and E7 proteins of HPV, including novel epitopes or peptides with specified features, and provide exclusivity for the treatment of persistent HPV infections and resulting diseases.

ISA101 is based on ISA Pharmaceuticals´ proprietary SLP® platform and is currently in clinical Phase I/II trials in cervical cancer and anal intraepithelial neoplasia (AIN).